The Fgfr2 W290R mouse model of Crouzon syndrome
1Dentistry, University of Toronto, 124 Edward Street, Toronto, Ontario, Canada. sg.gong@dentistry.utoronto.ca
Purpose:
This study aimed to review and discuss the utility of the Fgfr2 (W290R) mouse mutant as a model of human Crouzon syndrome.
Methods:
A review of current and past scientific literature on Fibroblast Growth Factor Receptor-2 (FGFR2) protein domain structure, FGFR mutations associated with human Crouzon syndrome, and phenotypic and molecular changes combined with recent observations and experimental data of the Fgfr2 (W290R) mouse mutant was conducted. A comparison of the Fgfr2 (W290R) mouse mutant with another mouse model of Crouzon syndrome, Fgfr2 (C342R) mouse mutant, was also performed. Finally, possible future research directions using the Fgfr2 (W290R) mutant mice were discussed.
Results:
The Fgfr2 (W290R) heterozygous mouse exhibits defects characteristic of human Crouzon syndrome. At the molecular level, the defects observed in the mouse mutant are due to the dysregulation of signaling of both the IIIb and IIIc isoforms of Fgfr2. The involvement of the IIIb isoform of FGFR2 in the etiopathology of Crouzon syndrome is a novel finding in the craniosynostosis literature field. Dysregulated signaling of both IIIb and IIIc isoforms causes a broad spectrum of changes that explain some of the defects observed clinically in humans. Several of the defects observed in the Fgfr2 (W290R) homozygous mouse mutant are attributable to a loss-of-function mechanism in contrast to the frequently reported gain-of-function receptor function associated with mutated FGF receptors in craniosynostosis.
Conclusions:
The Fgfr2 ( W290R ) mouse model can be used as a model system to further investigate the cellular, molecular, and biochemical mechanisms of Crouzon syndrome.
Insights
The Fgfr2 (W290R) mouse model effectively mimics human Crouzon syndrome, revealing novel insights into FGFR2 signaling pathways and craniosynostosis mechanisms.
Area of Science:
- Genetics and Developmental Biology
- Molecular Medicine
- Craniosynostosis Research
Background:
- Crouzon syndrome is a genetic disorder characterized by premature fusion of skull bones.
- Fibroblast Growth Factor Receptor-2 (FGFR2) mutations are strongly associated with craniosynostosis syndromes, including Crouzon syndrome.
- Understanding the precise molecular mechanisms underlying these syndromes is crucial for developing effective treatments.
Purpose of the Study:
- To evaluate the utility of the Fgfr2 (W290R) mouse mutant as a model for human Crouzon syndrome.
- To review and discuss the existing literature on FGFR2 structure, mutations, and associated phenotypes.
- To explore potential future research avenues using this specific mouse model.
Main Methods:
- Comprehensive literature review of FGFR2, Crouzon syndrome genetics, and mouse model data.
- Analysis of phenotypic and molecular changes in the Fgfr2 (W290R) mouse mutant.
- Comparative analysis with another Crouzon syndrome mouse model, Fgfr2 (C342R).
Main Results:
- The Fgfr2 (W290R) heterozygous mouse displays phenotypes consistent with human Crouzon syndrome.
- Molecular defects stem from dysregulated signaling of both FGFR2 IIIb and IIIc isoforms, with IIIb involvement being a novel finding.
- Observed defects in homozygous mutants suggest a loss-of-function mechanism, contrasting with typical gain-of-function mutations in craniosynostosis.
Conclusions:
- The Fgfr2 (W290R) mouse model is a valuable tool for studying Crouzon syndrome.
- This model facilitates further investigation into the cellular, molecular, and biochemical underpinnings of the syndrome.
- It offers a platform for exploring novel therapeutic strategies targeting FGFR2 signaling.
More Related Videos
07:40Dissection of the Auditory Bulla in Postnatal Mice: Isolation of the Middle Ear Bones and Histological Analysis
Published on: January 4, 2017
05:44Concurrent Collection of Fetal Murine Brain and Serum to Assess Effects of Maternal Diet on Nutrition and Neurodevelopment in Neurofibromatosis Type 1
Published on: May 17, 2024
